A Trial of Selinexor, Ruxolitinib and Methylprednisolone

NCT06225310 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma in Relapse
Multiple Myeloma, Refractory

Interventions

DRUG: Selinexor
DRUG: Ruxolitinib
DRUG: Methylprednisolone

Sponsor

Oncotherapeutics